Brokerages predict that ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) will announce ($0.18) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for ESSA Pharma’s earnings. ESSA Pharma reported earnings per share of ($0.19) in the same quarter last year, which would indicate a positive year over year growth rate of 5.3%. The company is scheduled to announce its next earnings report on Wednesday, December 13th.

On average, analysts expect that ESSA Pharma will report full year earnings of ($0.55) per share for the current year, with EPS estimates ranging from ($0.62) to ($0.49). For the next fiscal year, analysts forecast that the business will post earnings of ($0.63) per share, with EPS estimates ranging from ($0.68) to ($0.57). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for ESSA Pharma.

EPIX has been the topic of several research analyst reports. Zacks Investment Research raised ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a report on Monday, September 11th. Dawson James reissued a “buy” rating on shares of ESSA Pharma in a report on Thursday, August 3rd. Bloom Burton cut ESSA Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th. Finally, ValuEngine cut ESSA Pharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $4.75.

WARNING: “Zacks: Analysts Anticipate ESSA Pharma Inc. (EPIX) to Announce -$0.18 EPS” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/09/25/zacks-analysts-anticipate-essa-pharma-inc-epix-to-announce-0-18-eps.html.

ESSA Pharma (EPIX) opened at 0.283 on Monday. The company’s market cap is $8.24 million. ESSA Pharma has a one year low of $0.26 and a one year high of $2.80. The firm’s 50-day moving average price is $0.29 and its 200-day moving average price is $0.29.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.